and R. P. P. hsa-miR-151 in EBV+DLBCLe cases compared to EBVDLBCL cases. Hsa-miR-146b and hsa-miR-222 showed high specificity for determining EBV+DLBCLe. The present study proposed a miRNA signature to get EBV+DLBCLe and our findings suggest that hsa-miR-146b and hsa-miR-222 could be biomarkers and therapeutic targets. Keywords: DLBCL, EBV, elderly, microRNA == INTRO == Epstein-Barr virus+diffuse large B-cell lymphoma of the seniors (EBV+DLBCLe) is recognized as a provisional entity in the latest World Health Business classification system[1]. It affects individuals older than 50 years with no prior documented immunodeficiency. This disorder has an unfavorable clinical course, even after anthracycline-based chemotherapy [2]. It is linked to EBV contamination, and its physiopathological characteristics are related to the presence of the disease itself, senescence, and immunological deterioration [3]. It can arise because the result of EBV latency protein expression, conversation with web host factors, and epigenetic mechanisms of gene regulation, including microRNA (miRNA) expression [4]. MiRNAs are small RNAs with 18 to 25 nucleotides that result from cleavage of a longer non-coding RNA; they can interfere with gene regulation by binding to the complex of RNA-induced silencing, causing repression of translation and influencing differentiation, proliferation, cell survival, and apoptosis [5]. On the basis of current findings reported in the literature, viral miRNAs appear to possess a small role in EBV+DLBCLe [6]. However , many of them are homologous with human being miRNAs, which may explain the highly aggressive behavior of this disease. Supporting this hypothesis, the results of recent studies indicate that miRNAs from EBV are directly related to oncogenesis in several biological processes such as B-cell activation, oxidative stress response, cytokine-mediated inflammation, transcription pathway activation, and apoptosis inhibition [6, 7]. Although miRNA expression profiling was recently explained for EBV+DLBCL in general [8] or using different methodologies (PAR-CLIP) in lymphoblastoid cell lines [9], to our knowledge, no characteristic pattern of miRNA expression has been determined for seniors patients, i. e., EBV+DLBCLe. Therefore , in this retrospective study, we Alanosine (SDX-102) characterized a Alanosine (SDX-102) signature profile for this entity and identified exclusive miRNAs that can be used as biomarkers and option therapeutic focuses on for EBV+DLBCLe. == RESULTS == ISH for EBV revealed that 9% of DLBCL cases (6 patients) in the pilot study were EBV+DLBCLe. This was consequently expanded with 23 new cases (multicenter study). The clinical top features of all patients included in the study (pilot and multicenter) are shown in Table1. == Table 1 . Clinical features and results of immunohistochemical classification, according to the Hans (2004) and Salles (2011) algorithms, in 94 DLBCL patients (pilot and multicenter) old 50 years or older, evaluated according to positivity to get EBV by ISH. == N/A = not available NC = not classifiable In the EBV+DLBCLe group (n=29), patients were old 51 to 88 years (median, 67 years). There have been 12 male and 17 female patients; 63% had advanced Ann Arbor stage disease, Alanosine (SDX-102) 55% had an IPI score 2, 41% had B symptoms, and 21% presented with extranodal involvement (gastrointestinal tract, skin, and breast). In the EBVDLBCL group (n=63), the median age was 63 years (range, 50 to 85 Alanosine (SDX-102) years). There have been 29 males and 36 females; 62% had advanced Ann Arbor stage disease, 69% had B symptoms, and 38% had extranodal involvement (gastrointestinal tract, skin, breast, lung, kidney, testis, and thyroid). The IPI was 2 in 45% of cases. The comparison ILF3 of the two groups revealed no statistical difference in relation to the clinical characteristics described above, except.